EUVIMEDEUVIMED entdecken
Crossref

ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma

Marco Ruella

Cancer Cell · 2023

DOI: 10.1016/j.ccell.2023.11.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2023. Verfasst von Marco Ruella. Beteiligte Einrichtung: Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Di…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neuroblastoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: NCI NIH HHS, Beckman Coulter Foundation, Office of National Intelligence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell immunotherapy in solid cancer is severely limited by the absence of ideal targets. In this issue of Cancer Cell, Bergaggio et al. find that anaplastic lymphoma kinase (ALK) inhibitors can enhance the function of ALK-specific CAR T cells against neuroblastoma by increasing target density in cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeuroblastomaHumansImmunotherapyProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesT-LymphocytesImmunotherapy, AdoptiveReceptors, Antigen, T-Cell

Substanzen

Receptors, Chimeric AntigenProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Division of Hematology and Oncology, Perelman School of Medicine at the…

Förderung

  • NCI NIH HHS
  • Beckman Coulter Foundation
  • Office of National Intelligence
  • Leukemia and Lymphoma Society
  • Hairy Cell Leukemia Foundation
  • Gabrielle's Angel Foundation for Cancer Research
  • Laffey-McHugh Foundation
  • National Institutes of Health

Zitieren

APA

Ruella, M. (2023). ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma. Cancer Cell. https://doi.org/10.1016/j.ccell.2023.11.009

Vancouver

Ruella M. ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma. Cancer Cell. 2023. doi:10.1016/j.ccell.2023.11.009

BibTeX
@article{Ruella2023,
  author = {Ruella, Marco},
  title = {ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma},
  journal = {Cancer Cell},
  year = {2023},
  doi = {10.1016/j.ccell.2023.11.009}
}
Kostenlos starten →